Corona Remedies IPO Allotment Update: GMP Hints at Strong 28% Listing Jump

The Corona Remedies IPO has become one of the most talked‑about public offerings on the Indian markets this December. Investors are watching closely. We from the investing community have seen strong demand, huge subscription numbers, and a rising Grey Market Premium (GMP). These trends point to a likely good debut on the listing day.

Who Is Corona Remedies?

• Founded: 2004, a branded pharmaceutical company in India.
• Therapy Areas: Specializes in women’s health, cardio‑metabolic care, pain management, and urology.
• Pan-India Network: Operates a wide distribution network across multiple states with thousands of medical representatives serving doctors and chemists.
• Brand Portfolio: Owns strong brands in niche and high-growth segments, focusing on chronic therapies.
• Financial Performance: Achieved ₹1,200 crore revenue in FY2025 with significant profit growth over the previous year.

Corona Remedies IPO: At a Glance

The Corona Remedies IPO opened on 8 December 2025 and closed on 10 December 2025.

Here are the key facts investors should know:

• Issue type: Book built offer for sale (OFS) by existing shareholders.
• Size: ₹655.37 crore (approx).
• Price band: ₹1,008 to ₹1,062 per share.
• Lot size: 14 shares (minimum).
• Listing: Expected on 15 December 2025 on BSE and NSE.
• Allotment date: Expected 11 December 2025.

Since this is a pure OFS, the company itself will not receive fresh capital from the IPO. Existing investors and promoters will sell their shares.

Massive Subscription Response

The IPO saw huge investor interest. At the close of bidding, the issue was subscribed 137.04 times overall.

Breakdown of categories:

• Qualified Institutional Buyers (QIBs): ~278 times.
• Non‑Institutional Investors (NIIs): ~208 times.
• Retail Investors: ~28 times.

This blockbuster subscription shows that big investors and small investors both jumped in with strong demand. Strong subscription is a positive sign. It usually means that many people want to buy the stock. When demand outstrips supply, listing gains become more likely.

Allotment Status: What You Should Know

Now that the subscription is closed, attention shifts to allotment. Based on official timelines, the allotment status was finalised on 11 December 2025.

If you applied for the IPO, you can check your allotment status now. Here’s how:

• Visit Bigshare Services, the official registrar’s portal.
• Search on the BSE or NSE websites with your PAN or application number.

If you get allotted shares, they should get credited to your demat account before the listing date, usually within 1–2 days after allotment.

GMP Trend: Strong Signals for Listing Jump

• What is GMP: Grey Market Premium (GMP) is an unofficial indicator where shares trade before listing on the stock exchange. A high GMP usually signals strong listing expectations.
• Current Trend: For the Corona Remedies IPO, GMP is hovering around ₹270 per share above the upper price band.
• Potential Listing Jump: At the upper band of ₹1,062, this indicates a ~25–28% gain on listing.
• Expected Listing Price: If GMP holds, shares could debut around ₹1,330–₹1,350 or higher.
• Important Note: GMP reflects market sentiment, not guaranteed returns. Actual listing prices can vary depending on market conditions.
• Investor Insight: Despite risks, a high GMP is a positive signal. Many investors view it as an opportunity for short-term gains.

Why the Strong Interest in Corona Remedies IPO

• Solid Pharma Growth Story: Corona Remedies operates in high-demand areas like women’s health and chronic therapies. It has shown strong margins and consistent profit growth, boosting investor confidence.
• Attractive Valuations: The IPO price band is considered fair compared to peers, making it appealing for investors looking for growth potential.
• Marketing and Brand Strength: The company has a large marketing reach and a diversified product portfolio, which supports sustainable growth and market presence.

Risks Every Investor Should Consider

We must be fair and balanced. Here are some risks to know:

1. OFS Means No Fresh Capital for Growth: Unlike many IPOs, the Corona Remedies IPO does not raise new funds for the business. As a result, the company will not be using the funds from the IPO for business expansion or research and development

2. Concentration Risks: Some brands and markets contribute disproportionately to revenue. If demand shifts or competition increases, growth could slow.

3. Industry Challenges: Regulatory changes, pricing pressures, or supply chain disruptions can impact pharmaceutical firms.

4. GMP Isn’t a Promise: Grey Market Premium can change quickly. It reflects sentiment, not guaranteed returns.

Listing Day Expectations

• Above Issue Price: Corona Remedies shares are expected to list above the IPO price band, supported by strong demand and Grey Market Premium (GMP).
• Estimated Gains: Current GMP indicates a potential 25–28% first-day gain, but actual prices may vary based on market conditions.
• Volatility Possible: While short-term gains are likely, price fluctuations on listing day are possible due to market sentiment and trading activity.

Conclusion

The Corona Remedies IPO grabbed investor attention with huge subscription numbers and strong GMP signals. A 28% potential listing jump suggests good short‑term interest. We from the investing world see this as a lively event in the IPO calendar. Yet, every investor should weigh their risk appetite and long‑term goals before making decisions. Whether you’re a short‑term trader hoping for the pop or a long‑term investor focusing on business fundamentals, the Corona Remedies IPO has become one to watch this December closely.

FAQS

 Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.